Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem Dec 15, 2022
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022 Nov 3, 2022
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Oct 20, 2022
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem Sep 19, 2022
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep 7, 2022
